Changes in cholinergic and glutamatergic markers in the striatum from a sub-set of subjects with schizophrenia

Brian Dean, Natalie Thomas, Chi Yu Lai, Wei J. Chen, Elizabeth Scarr

Research output: Contribution to journalArticleResearchpeer-review

7 Citations (Scopus)


Background/objectives: Having separated a sub-group of people with schizophrenia based on a marked loss of cortical [3H]pirenzepine binding (MRDS); we wished to determine if MRDS had lower levels of [3H]pirenzepine and other muscarinic receptor antagonist binding to the striatum and if this was due to loss of pre- or post-synaptic neurons or glia measured using surrogate markers (25kilodalton synaptosomal-associated protein (SNAP 25), postsynaptic density protein 95 (PSD 95), glial fibrillary acidic protein (GFAP) 41/43) of cell number. Methods: [3H]pirenzepine, [3H]AF-DX 384 and [3H]4-DAMP binding to the striatum from 37 subjects with schizophrenia (19 MRDS) and 20 controls as well as SNAP 25, PSD 95 and GFAP 41/43 in crude particulate membrane were measured. Results: [3H]pirenzepine and [3H]AF-DX 384 binding to the striatum were significantly lower in schizophrenia due to lower binding of both radioligands in the striatum from MRDS. Levels of PSD 95 were higher in schizophrenia, predominantly due to higher levels in MRDS. Conclusions: Our data suggest muscarinic M1 ([3H]pirenzepine) and M2 and/or M4 receptors ([3H]AF-DX 384) are lower in the striatum from MRDS which could mediate inappropriate adaption to internal and external cues which, in turn, would affect motivation, cognition and motor control. Increased levels of PSD 95 could indicate increased post-synaptic boutons or changes in NMDA receptor-mediated signalling in MRDS.

Original languageEnglish
Pages (from-to)83-88
Number of pages6
JournalSchizophrenia Research
Issue number1-3
Publication statusPublished - 1 Dec 2015
Externally publishedYes

Cite this